DTDeng Tang

Deng Tang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Deng Tang has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Gang Chen

    Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China

    2 shared publications
  • Mi Su

    West China School of Basic Medical Sciences & Forensic Medicine Sichuan University Chengdu Sichuan People's Republic of China

    2 shared publications
  • Siqi Lan

    West China School of Basic Medical Sciences & Forensic Medicine Sichuan University Chengdu Sichuan People's Republic of China

    2 shared publications
  • Yufei Tang

    West China School of Basic Medical Sciences & Forensic Medicine Sichuan University Chengdu Sichuan People's Republic of China

    2 shared publications
  • Bin-Tong Yin

    Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, People’s Republic of China

    1 shared publication
  • Chengyi Zhu

    Division of Natural and Applied Sciences, Synear Molecular Biology Lab Duke Kunshan University People's Republic of China

    1 shared publication

Latest Publications

  • Deficient Mismatch Repair Represents a Distinct Molecular Feature of Early‐Onset Colorectal Cancer in Chinese Single‐Center Cohort

    by Deng Tang, Zhigang Mao, Siqi Lan, Yali Song, Si Chen, Yuemei Chen, Mi Su, Yufei Tang, Chengyi Zhu, Ruiting Yan, et al.

    Early‐onset colorectal cancer (EOCRC), defined as colorectal cancer diagnosed before the age of 50 years, is increasing worldwide, with a similar trend emerging in China. However, the clinicopathological and mismatch repair features of EOCRC in Chinese patients remain insufficiently characterized. We retrospectively reviewed 23,414 colorectal neoplasia cases diagnosed at West China Hospital between November 2008 and June 2023. Among these, 4,159 colorectal cancer cases with complete immunohistochemical assessment of MLH1, PMS2, MSH2, and MSH6 were included in the primary analysis. Clinicopathological characteristics and mismatch repair status were compared between EOCRC and late‐onset colorectal cancer (LOCRC), with additional stratification by documented family history. Multivariable logistic regression was used to evaluate the independent association between early‐onset status and deficient mismatch repair (dMMR). Compared with LOCRC, EOCRC showed less favorable clinicopathological features, including higher proportions of poor differentiation, T4 tumors, nodal involvement, and advanced TNM stage. EOCRC also had a significantly higher prevalence of dMMR. In multivariable analysis, early‐onset status was independently associated with dMMR in the overall cohort (adjusted OR, 2.27; 95% CI, 1.60–3.22; p < 0.001), and among patients without documented family history (adjusted OR, 1.95; 95% CI, 1.33–2.86; p < 0.001). Patterns of MMR protein loss differed according to documented family history status. In conclusion, EOCRC in this Chinese MMR‐tested cohort was associated with more advanced clinicopathological features and a higher prevalence of dMMR, supporting routine MMR assessment in young patients with colorectal cancer.

  • Open Access

    NG25 Enhances Anti-Tumor Immunity in KRAS-Mutant Colorectal Cancer

    by Qi Xiang, Zhigang Mao, Qizhao Ma, Mi Su, Deng Tang, Siqi Lan, Yufei Tang, Ji Zhang, Yufang Wang

    Purpose: The poor prognosis of KRAS-mutant colorectal cancer is attributed to its immunosuppressive tumor microenvironment and the lack of effective targeted therapies. Transforming growth factor-β-activated kinase 1 (TAK1), serving as a critical upstream regulator of both the NF-κB and MAPK signaling pathways, promotes tumor progression through its aberrant activation. In this study, we aimed to investigate the anti-tumor and immunomodulatory effects of the TAK1 inhibitor NG25 in KRAS-mutant colorectal cancer, focusing on its impact on T cell differentiation, PD-L1 expression, and tumor immune microenvironment remodeling. Methods: The anti-tumor and immune-enhancing effects of NG25 were evaluated through an in vitro tumor cell-lymphocyte co-culture system, and the orthotopic colorectal cancer models in both immunodeficient Balb/c nude mice and immunocompetent Balb/c mice. Results: NG25 significantly suppressed the tumor progression in immunocompetent Balb/c mice, while concurrently increasing the spleen and thymus indices and promoting the proliferation of T and B lymphocytes. In tumor microenvironment, NG25 treatment could promote CD8⁺ T cell infiltration and increase the proportion of CD3⁺CD8⁺ T cell subsets. Mechanistic studies revealed that NG25 downregulates PD-L1 expression on both KRAS-mutant tumor cells and T cells through inhibiting TAK1/NF-κB axis. However, this regulatory effect was absent in KRAS wild-type tumor cells. Conclusion: NG25 blocks the NF-κB signaling pathway by targeting TAK1, remodels the immunosuppressive microenvironment of KRAS-mutated colorectal cancer, reduces PD-1 expression and enhances the anti-tumor effect of CD8⁺ T cells. This study provides a theoretical basis for TAK1-targeted therapy and offers a new strategy for immunotherapy of KRAS-mutated colorectal cancer.


  • Open Access

    Expression Profile and Molecular Basis of Cyclin-Dependent Kinases Regulatory Subunit 2 in Endometrial Carcinoma Detected by Diversified Methods

    by Li Gao, Gang Chen, Zi-Qian Liang, Jian-Di Li, Dong-Ming Li, Yu-Lu Tang, Deng Tang, Zhi-Guang Huang, Jun-Hong Chen, Jia-Yuan Luo, et al.

    Purpose: Our purpose was to systematically appraise the clinicopathological significance and explore the molecular bases of CKS2 in endometrial carcinoma.Patients and Methods: We measured the clinicopathological significance of CKS2 using diverse methods of public RNA-seq, microarrays, and in-house tissue microarrays to investigate the molecular basis of CKS2 in endometrial carcinoma through upstream transcriptional analysis, immune infiltration correlation analysis, and co-expression analysis.Results: Both the analysis for public RNA-seq plus the microarray data and in-house tissue microarray confirmed the significant overexpression of CKS2 in a total of 1,021 endometrial carcinoma samples compared with 279 non-cancer endometrium samples (SMD = 2.10, 95% CI = 0.72–3.48). The upregulated CKS2 was significantly related to the lymph node metastasis and advanced clinical grade of endometrial carcinoma patients (p < 0.001). Mutation types such as amplification and mRNA occurred with high frequency in the CKS2 gene in endometrial carcinoma patients. A series of miRNAs and transcription factors, such as hsa-miR-26a, hsa-miR-130a, hsa-miR-30, E2F4, MAX, and GABPA, were predicted to regulate the transcription and expression of CKS2. Significant links were found between CKS2 expression and the infiltration level of B cells, CD4+ T cells, and neutrophils in endometrial carcinoma. CKS2-coexpressed genes were actively involved in pathways such as the mitotic cell cycle process, PID aurora B pathway, and prolactin signaling pathway.Conclusion: The overexpressed CKS2 showed positive correlations with the clinical progression of endometrial carcinoma and was associated with various cancer-related biological processes and pathways, showing potential as a promising clinical biomarker for endometrial carcinoma.


  • Open Access

    Down-Regulation of Activating Transcription Factor 3 (ATF3) in Hepatoblastoma and Its Relationship with Ferroptosis

    by Jing-Xiao Li, Jin-Shu Pang, Bin-Tong Yin, Gang Chen, Jun-Hong Chen, Jia-Yuan Luo, Xia Yang, Li-Ting Qin, Jiang-Hui Zeng, Peng Chen, et al.

    Purpose: The molecular mechanisms and signal pathways of ferroptosis in hepatoblastoma (HB) have not yet been clarified. In previous studies, activating transcription factor 3 (ATF3) was reported to be correlated with several tumors, but the clinical significance of ATF3 has never been determined. Herein, we investigated the clinicopathological value and mechanisms of ATF3 in regulating ferroptosis in HB. Methods: The mRNA microarray and RNA-sequencing data of 402 samples from our hospital and public databases were used to estimate ATF3 expression and assess its clinical role in HB. The standard mean difference (SMD) and summary receiver operating characteristic curves were utilized to judge the discrimination ability of ATF3 between HB and non-HB liver tissues. We examined the expression variation of ATF3 in HB cells after the treatment with erastin. We also predicted the target genes of ATF3 as a transcriptional factor from public Chromatin Immunoprecipitation-sequencing data and selected the ferroptosis-related genes for a signaling pathway analysis. Results: In ten series, the pooled SMD for ATF3 was − 0.91, demonstrating that ATF3 expression was predominantly lower in HB than in non-HB liver tissues. ATF3 down-regulation showed moderate potential to distinguish HB from non-HB liver tissues (area under curves = 0.83, 95% confidence interval = 0.79– 0.86). Altogether, 4855 putative targets of ATF3 as a transcriptional factor were collected, among which, 60 genes were ferroptosis-related. Conclusion: The down-regulated ATF3 expression may play a vital role in the occurrence of HB possible partially by regulating ferroptosis.


  • Smooth muscle actin immunostain is useful for the diagnosis of Trichomonas vaginalis in vaginal smears

    by Ni Fang, Deng Tang, Hanjie Zhang, Jie Zeng

    Objective The parasite Trichomonas vaginalis (T. vaginalis) causes one of the most common non-viral sexually transmitted infections in humans. T. vaginalis is notorious for its inconspicuous appearance in vaginal smears. It can be missed under the microscope. Method In the present study, we investigate the immunoreactivity of T. vaginalis to smooth muscle actin (SMA) in the vaginal smear. Result T. vaginalis trophozoite and pseduocyst are immunoreactive for SMA in all of the study group cases (n = 21) and in none of the control group cases (n = 21). Thus, SMA immunostain is a sensitive method for the demonstration of T. vaginalis. Moreover, the protozoan attains a conspicuous and unique appearance. By SMA immunohistochemical stain, the apperance of T. vaginalis floated freely or located in the cytoplasm of the epithelial cells is easily identified. Conclusion We recommend performing SMA immunostain in every vaginal smear with clinical or pathologic suspicion of trichomoniasis.